Charles River Laboratories Reaffirms Outlook For FY24 Revenue Growth Of 1.0%-4.0% And Adj EPS Of $10.90-$11.40, Est $11.02
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories (CRL) has reaffirmed its FY24 revenue growth outlook of 1.0%-4.0% and adjusted EPS guidance of $10.90-$11.40, aligning with an estimated EPS of $11.02. The company expects modest demand improvements in the second half of the year, maintaining its yearly projections despite slight adjustments to quarterly expectations.

May 09, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Charles River Laboratories reaffirms its FY24 revenue and EPS guidance, indicating stable financial expectations and potential demand growth.
Reaffirming financial guidance, especially in a volatile market, can be seen as a positive signal to investors, suggesting management's confidence in the company's stability and growth prospects. The specific mention of expected demand improvements in the second half of the year further supports a positive outlook, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100